MARKET

ALEC

ALEC

Alector
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.80
-0.68
-3.68%
After Hours: 17.99 +0.19 +1.07% 18:15 04/16 EDT
OPEN
18.40
PREV CLOSE
18.48
HIGH
18.45
LOW
17.04
VOLUME
757.21K
TURNOVER
--
52 WEEK HIGH
34.89
52 WEEK LOW
9.12
MARKET CAP
1.42B
P/E (TTM)
-7.2879
1D
5D
1M
3M
1Y
5Y
Replay: Investing in Alzheimer’s Treatment — Jupiter Orphan Therapeutics CEO Joins Fireside Chat
Christer Rosén, Chairman-CEO & Founder of Jupiter Orphan Therapeutics, Inc, Raymond “Scott” Turner MD, Professor Neurology, Georgetown University (Alzheimer’s scientist) and Mark Dant, Executive Director, Ryan Foundation IPO Edge, in partnership with The P...
IPO-Edge.com · 03/30 17:23
Alector to Present at Stifels 3rd Annual CNS Day
SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating offic...
GlobeNewswire · 03/25 21:05
Thinking about buying stock in PLBY Group, Livexlive Media, Alector, Pixelworks, or Frequency Therapeutics?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PLBY, LIVX, ALEC, PXLW, and FREQ.
PR Newswire - PRF · 03/24 13:31
Investing in Alzheimers Treatment: Join Jupiter Orphan Therapeutics for Fireside Chat March 30
Christer Rosén, Chairman-CEO & Founder of Jupiter Orphan Therapeutics, Inc, Raymond “Scott” Turner MD, Professor Neurology, Georgetown University (Alzheimer’s scientist) and Mark Dant, Executive Director, Ryan Foundation IPO Edge, in partnership with The P...
IPO-Edge.com · 03/23 18:53
DJ Alector Up Over 14%, on Pace for Largest Percent Increase in Over a Year -- Data Talk
Dow Jones · 03/19 18:47
Alector up 18% after patent application published for Alzheimer's program
Shares of Alector (ALEC) are up 18.1% to $21.18 after the U.S. Patent and Trademark office yesterday published the company's patent application for its anti-MS4A4A program used to develop Alzheimer's disease treatments.The
Seekingalpha · 03/19 15:04
Clovis Oncology, Marker Therapeutics leads healthcare gainers; Idera Pharmaceuticals, Praxis Precision Medicines among major losers
Gainers: Clovis Oncology (CLVS) +43%, Marker Therapeutics (MRKR) +23%, Alector (ALEC) +17%, Aravive (ARAV) +14%, Ortho Clinical Diagnostics (OCDX) +8%.Losers: Idera Pharmaceuticals (IDRA) -62%, Praxis Precision Medicines (PRAX) -13%,  Acutus Medical (AFIB)...
Seekingalpha · 03/19 15:04
Alector to Present at the Barclays Global Healthcare Conference
GlobeNewswire · 03/04 21:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALEC. Analyze the recent business situations of Alector through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALEC stock price target is 31.88 with a high estimate of 41.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 181
Institutional Holdings: 50.85M
% Owned: 63.90%
Shares Outstanding: 79.58M
TypeInstitutionsShares
Increased
37
2.81M
New
16
1.75M
Decreased
50
6.65M
Sold Out
22
684.61K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Co-Founder/Director
Tillman Gerngross
President/Chief Operating Officer
Shehnaaz Suliman
Chief Executive Officer/Co-Founder/Director
Arnon Rosenthal
Vice President - Finance
Calvin Yu
Other
Robert King
Other
Sabah Oney
Other
Siang-Shu Robert
Other
Robert Paul
Lead Director/Independent Director
Louis Lavigne
Independent Director
Paula Hammond
Independent Director
Terry McGuire
Independent Director
Richard Scheller
Independent Director
David Wehner
Independent Director
Kristine Yaffe
No Data
About ALEC
Alector, Inc. is a clinical-stage biopharmaceutical company focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL101, Al002 and AL003. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).

Webull offers kinds of Alector Inc stock information, including NASDAQ:ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.